Please assess the completion status of the following clinical trial:

Trial Title: Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* ECOG Performance Status 0-1~* Favorable or intermediate MSKCC or Heng risk score~* Biopsy (primary tumour or metastases) confirming the diagnosis of predominantly clear cell RCC~* Resectable asymptomatic in situ primary (asymptomatic primary is defined as the absence of symptoms which can be exclusively assigned to the primary tumor such as flank pain and/or gross hematuria necessitating blood transfusion.)~* Tumour suitable to nephrectomy in the opinion of the urologist. Patients with Inferior vena cava thrombosis can be included~* Documented metastatic disease (CT scan or MRI)~* Life expectancy \> or = 24 weeks~* Up to three different metastatic sites~* ≥ 3 metastatic lesions~* Platelets \> 100,000/ml~* Haemoglobin \> 9.0 g/dl~* neutrophils \>1,500/mm3~* Bilirubin \< or = 2 mg/dl, except for patients affected by Gilbert's syndrome~* AST and ALT \< or = 2.5 times the UNL~* Serum albumin \> the LNL~* Patients of childbearing age should use contraceptive methods during the study~Exclusion Criteria:~* Prior surgery or systemic treatment for mRCC~* Bilateral RCC~* Brain and liver metastases~* Non-clear-cell histology~* Poor prognosis as defined by MSKCC or Heng criteria~* Documented widespread disease (\> or =4 metastatic organ sites)~* Oligometastatic disease suitable of metastasectomy (\<3 lesions confined at one organ site)~* Symptomatic primary tumour at presentation~* High surgical risk in the opinion of the urologist~* Patients with \> 3 of the following surgical risk factors are not eligible:~  * Serum albumin CTCAE v 4.0 grade 2 or worse~ * Serum LDH \> 1.5 times upper limit of normal~ * Symptoms at presentation due to metastases~ * Clinical stage T4 disease~ * History of malabsorption syndrome~* Pregnant or breastfeeding women~* Concomitant cardiac disorders: cardiac failure NYHA\> 2; Acute coronary syndrome or myocardial infarction or severe or unstable angina within the last 6 months as well as uncontrolled hypertension (sistolic\>160, diastolic\>90), arrhytmia requiring treatment (except for beta blockers or digossin)~* Uncontrolled diabetes~* Deep phlebitis not treated with LMWH or arterial thrombosis within the last 6 months~* HIV infection~* Active infections (\> Grade 2 NCI-CTC v.3.0)~* Other cancer within the previous 5 years (except for in situ skin carcinoma, superficial bladder Ta, Tis, T1 and carcinoma of the cervix or every cancer with curative treatment within 5 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A: TKIs (Type: ACTIVE_COMPARATOR): sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
- B: TKIs + Cytoreductive Nephrectomy (Type: EXPERIMENTAL): Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously

Based on this trial design, predict the completion outcome and termination type (if applicable).